Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline.

Authors

Sridhar Chaganti, Christopher P Fox, Bernard D Maybury, Cathy Burton, Sally F Barrington, Timothy Illidge, Nagesh Kalakonda, Toby A Eyre, Pam McKay, Andrea Kuhnl, Kate Cwynarski, Andrew J Davies, BSH Committee

Published in

British journal of haematology. May 19, 2025. Epub May 19, 2025.

Abstract

Time to progression is the strongest predictor of outcome in relapsed diffuse large B-cell lymphoma. Second-line treatment with chimeric antigen receptor (CAR) T-cell therapy is recommended for patients with progression within 12 months of first-line chemoimmunotherapy. In patients with late relapse, platinum-based chemotherapy followed by high-dose chemotherapy with autologous stem cell rescue is recommended. In second relapse, CAR T-cell or CD3xCD20 bispecific antibody therapy is recommended in eligible patients. Other treatment options are available for less fit patients. Specific recommendations are made on diagnostic immunohistochemistry, bendamustine use and bridging to CAR T-cell therapy.

PMID:
40384597
Bibliographic data and abstract were imported from PubMed on 19 May 2025.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.